CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced that on Monday, December 2, 2019, it will host a key opinion leader (KOL) meeting in New York City on the current treatment landscapes and unmet medical needs of patients with Merkel cell carcinoma, triple-negative breast cancer, solid tumors and the state-of-the-art treatment in the induction of Immunogenic Cell Death.
This event will feature presentations from KOLs George Ansstas, MD, Washington University of Medicine in St. Louis, Chaitali Nangia, MD, Chan Soon-Shiong Institute for Medicine, and Clint Allen, MD, Johns Hopkins Kimmel Cancer Center, as well as Dr. Patrick Soon-Shiong, Chief Executive Officer and Chairman of NantKwest.
NantKwest’s management team will also provide pipeline updates on their haNK and PD-L1.t-haNK programs utilizing the Company’s Activated Natural Killer (aNK) cell platform to target these diseases. This platform harnesses the power of the innate immune system and is uniquely positioned to provide broadly available, off-the-shelf cell therapies capable of being administered in the outpatient setting.
Clint Allen, MD is an Associate Professor of Otolaryngology-Head and Neck Surgery at the Johns Hopkins School of Medicine, Principal Investigator of the Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, NIH. His research focuses on understanding how the immune system responds to squamous cell carcinoma of the head and neck, and how this can be enhanced therapeutically. He leads a large pre-clinical and clinical laboratory program focused on translational pre-clinical studies in syngeneic models of squamous cell carcinoma and the assessment of clinical trial specimens. He is the director of the inpatient Otolaryngology consultation service at the NIH Clinical Center and maintains a surgical practice for the Johns Hopkins School of Medicine based out of Suburban Hospital in Bethesda, MD.
George Ansstas, MD is an Assistant Professor of Medicine, Section of Medical Oncology, Division of Oncology at Washington University School of Medicine. Dr. Ansstas's clinical expertise includes brain tumors, neuro-oncology, skin cancer, and melanoma. He received his medical degree from University of Tishreen, Latakia, Syria in 2001. Dr. Ansstas completed a fellowship in hematology and oncology at Washington University, St. Louis.
Chaitali Nangia, MD is an Hematologist/Oncologist based in Costa Mesa, California and is affiliated with Hoag Hospital System. She received her medical degree from Lady Hardinge Medical College in New Delhi, India and completed her residency in Internal Medicine at Resurrection Westlake Medical Center in Illinois. She then completed her Fellowship in Hematology/Oncology at the Henry Ford Hospital in Michigan. She worked as an Associate Professor at University of California-Irvine and as an Associate Program Director at University of California-Irvine Hematology/Oncology Fellowship Program prior to her current role. She acted as the principal investigator for several clinical trials and has been an author of several publications.
This event is intended for institutional investors, sell-side analysts, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. Members of the media and the public are invited to participate via the live webcast, which can be accessed through our company website at https://nantkwest.com/nantkwest-key-opinion-leader-event/. The event is expected to start at noon EST on Monday, December 2, 2019.
NantKwest (NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and virally induced infectious diseases. We are the leading producer of clinical dose forms of off-the-shelf Natural Killer (NK) cell therapies. Our activated NK cell platform is designed to destroy cancer and virally infected cells from the body. The safety of our optimized, activated NK cells, as well as their activity against a broad range of cancers, have been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest’s goal is to transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies. For more information, please visit https://nantkwest.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying that NantKwest will be successful in improving the treatment of cancer. Risks and uncertainties related to this endeavor include, but are not limited to, obtaining FDA approval of NantKwest’s NK cells as well as other therapeutics as part of the NANT Cancer Vaccine platform as a cancer treatment.
Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.
These and other risks regarding NantKwest’s business are described in detail in its Securities and Exchange Commission filings, including in NantKwest’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.